We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

39 hedge funds and large institutions have $14.3M invested in Titan Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,400% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 1

515% more call options, than puts

Call options by funds: $1.91M | Put options by funds: $311K

440% more capital invested

Capital invested by funds: $2.65M → $14.3M (+$11.7M)

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

160% more funds holding

Funds holding: 15 → 39 (+24)

Holders
39
Holders Change
+24
Holders Change %
+160%
% of All Funds
1.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
7
Reduced
2
Closed
1
Calls
$1.91M
Puts
$311K
Net Calls
+$1.6M
Net Calls Change
+$312K

Top Buyers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
+$2.88M
2
State Street
State Street
Massachusetts
+$1.77M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.58M
4
Northern Trust
Northern Trust
Illinois
+$980K
5
BIT
BlackRock Institutional Trust
California
+$767K

Top Sellers

Rank Fund Capital Flow
1
SIM
Spark Investment Management
New York
-$298K
2
DADC
D.A. Davidson & Co
Montana
-$170K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$26K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.11M +$1.58M +74 +88%
BFA
2
BlackRock Fund Advisors
California
$2.69M +$2.88M +135 +13,500%
State Street
3
State Street
Massachusetts
$1.63M +$1.77M +83 New
Northern Trust
4
Northern Trust
Illinois
$1.05M +$980K +46 +657%
BIT
5
BlackRock Institutional Trust
California
$717K +$767K +36 New
Geode Capital Management
6
Geode Capital Management
Massachusetts
$595K +$192K +9 +43%
Goldman Sachs
7
Goldman Sachs
New York
$539K +$575K +27 New
BIM
8
BlackRock Investment Management
Delaware
$392K +$426K +20 New
Bank of New York Mellon
9
Bank of New York Mellon
New York
$347K +$213K +10 +125%
TCIM
10
TIAA CREF Investment Management
New York
$346K +$383K +18 New
GS
11
Gagnon Securities
New York
$340K +$362K +17 New
VKH
12
Virtu KCG Holdings
New York
$269K +$298K +14 New
California State Teachers Retirement System (CalSTRS)
13
California State Teachers Retirement System (CalSTRS)
California
$216K +$234K +11 New
Bank of America
14
Bank of America
North Carolina
$204K – – –
Stifel Financial
15
Stifel Financial
Missouri
$182K +$192K +9 New
AllianceBernstein
16
AllianceBernstein
Tennessee
$168K +$192K +9 New
Charles Schwab
17
Charles Schwab
California
$165K +$170K +8 New
TA
18
Teachers Advisors
New York
$165K +$170K +8 New
California Public Employees Retirement System
19
California Public Employees Retirement System
California
$154K – – –
RHBC
20
R.H. Bluestein & Co
Michigan
$109K +$128K +6 New
New York State Common Retirement Fund
21
New York State Common Retirement Fund
New York
$106K +$106K +5 New
TDC
22
Thompson Davis & Co
Virginia
$89K +$21.3K +1 +33%
CS
23
Credit Suisse
Switzerland
$87K +$85.2K +4 New
Citadel Advisors
24
Citadel Advisors
Florida
$85K +$85.2K +4 New
RhumbLine Advisers
25
RhumbLine Advisers
Massachusetts
$72K +$85.2K +4 New
1
2 3

TTNP Hedge Fund Activity: Q2 2016 in Review

39 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q2 2016, worth a combined $14.3M — up 440% from $2.65M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new TTNP positions and 1 closed out — a net gain of 24 holders — while 7 added to existing stakes and 2 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $2.88M. The largest seller was Spark Investment Management, cutting an estimated $298K.

  • 39 institutional investors held Titan Pharmaceuticals (TTNP) as of Q2 2016, up from 15 in Q1 2016.
  • Funds reported $14.3M of Titan Pharmaceuticals stock for Q2 2016, up 440% quarter-over-quarter.
  • 25 funds opened new Titan Pharmaceuticals positions in Q2 2016 and 1 closed out, a net change of +24 holders.
  • The largest Titan Pharmaceuticals buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $2.88M added.
  • The largest Titan Pharmaceuticals seller in Q2 2016 was Spark Investment Management, an estimated $298K sold.

Based on aggregated 13F filings for Q2 2016.